DrCarola Venturini

Dr Venturini's research tackles the global challenge of antimicrobial resistance (AMR), delivering real-world impact for sustainable food production and improved health outcomes. Her work has advanced understanding of AMR mechanisms and bacterial adaptation (16 papers, >560 citations; 15 invited talks) defining parameters to track AMR flow and identify high-risk pathogens in animals and humans, informing surveillance, containment strategies, and public health responses (Venturini et al. 2020 AAC, featured in NEJM Journal Watch; FASEB J 2010; Nat Gen 2015). Her work on plasmid-mediated resistance and genomic variability underpins current funding for comparative studies of animal and human reservoirs. She pioneered development of phage-based antibacterial therapies (11 papers, >800 citations; 12 invited talks). As CI and project lead on NHMRC GNT1103722, she established curated phage banks and protocols enabling the world’s first intravenous phage therapy trial (Nat Microbiol 2020, >490 citations) and ongoing clinical use. She led studies on phage-host interactions critical for therapeutic success (Venturini et al. 2020 FASEB J), authored invited reviews in top journals (EMBO Mol Med IF 14; Clin Infect Dis IF 21), and secured major funding (incl. current NHMRC Ideas ). These achievements are supported by her strong global collaboration network (EU, USA, India, Vietnam).